RxDoctor Payments Data

Stephanie Silverman

Nurse Practitioner · Longview, TXNPI 1679941363

Payments from drug & device makers

$7,809in general payments, 2019–2025

Across 493 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$881
  • AbbVie$829
  • AstraZeneca$781
  • Pfizer$612
  • Bayer$606
  • GSK$483
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,70399%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,809 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$334,816
Medicare patients
299
Services billed
13,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide229$334,421
FarxigaDapagliflozin Propanediol107$91,818
JardianceEmpagliflozin76$84,624
MounjaroTirzepatide45$62,963
EliquisApixaban49$55,292
MyrbetriqMirabegron41$34,132
LinzessLinaclotide46$29,136
Tresiba Flextouch U-200Insulin Degludec23$25,462
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$22,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,323
Tresiba Flextouch U-100Insulin Degludec31$20,869
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$16,549
JanuviaSitagliptin Phosphate13$12,331
NovologInsulin Aspart22$9,500
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$7,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$881$343,921251 claims
AstraZenecaFarxiga$781$91,818107 claims
Boehringer IngelheimJardiance$210$84,62476 claims
Lilly USA, LLCMounjaro, Humalog$470$67,21856 claims
PfizerEliquis$612$55,29249 claims
Astellas Pharma US IncMyrbetriq$259$34,13241 claims
AbbVieLinzess$829$29,13646 claims
GSKTrelegy Ellipta$483$22,32326 claims
MerckJanuvia$261$12,33113 claims
Sanofi-aventis U.S. LLCLantus$82$2,67614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →